1. Home
  2. DNLI vs TPC Comparison

DNLI vs TPC Comparison

Compare DNLI & TPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DNLI
  • TPC
  • Stock Information
  • Founded
  • DNLI 2013
  • TPC 1894
  • Country
  • DNLI United States
  • TPC United States
  • Employees
  • DNLI N/A
  • TPC N/A
  • Industry
  • DNLI Biotechnology: Biological Products (No Diagnostic Substances)
  • TPC General Bldg Contractors - Nonresidential Bldgs
  • Sector
  • DNLI Health Care
  • TPC Consumer Discretionary
  • Exchange
  • DNLI Nasdaq
  • TPC Nasdaq
  • Market Cap
  • DNLI 2.1B
  • TPC 2.5B
  • IPO Year
  • DNLI 2017
  • TPC N/A
  • Fundamental
  • Price
  • DNLI $14.19
  • TPC $63.93
  • Analyst Decision
  • DNLI Strong Buy
  • TPC Strong Buy
  • Analyst Count
  • DNLI 16
  • TPC 3
  • Target Price
  • DNLI $33.62
  • TPC $60.67
  • AVG Volume (30 Days)
  • DNLI 2.0M
  • TPC 547.6K
  • Earning Date
  • DNLI 11-05-2025
  • TPC 11-05-2025
  • Dividend Yield
  • DNLI N/A
  • TPC N/A
  • EPS Growth
  • DNLI N/A
  • TPC N/A
  • EPS
  • DNLI N/A
  • TPC N/A
  • Revenue
  • DNLI N/A
  • TPC $4,770,779,000.00
  • Revenue This Year
  • DNLI N/A
  • TPC $23.30
  • Revenue Next Year
  • DNLI $802.87
  • TPC $12.61
  • P/E Ratio
  • DNLI N/A
  • TPC N/A
  • Revenue Growth
  • DNLI N/A
  • TPC 12.03
  • 52 Week Low
  • DNLI $10.57
  • TPC $18.34
  • 52 Week High
  • DNLI $33.33
  • TPC $65.00
  • Technical
  • Relative Strength Index (RSI)
  • DNLI 41.95
  • TPC 71.89
  • Support Level
  • DNLI $14.63
  • TPC $59.94
  • Resistance Level
  • DNLI $15.69
  • TPC $63.76
  • Average True Range (ATR)
  • DNLI 0.68
  • TPC 1.90
  • MACD
  • DNLI -0.14
  • TPC 0.06
  • Stochastic Oscillator
  • DNLI 0.99
  • TPC 87.34

About DNLI Denali Therapeutics Inc.

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

About TPC Tutor Perini Corporation

Tutor Perini Corp offers general contracting, construction management, and design-build services to private and public customers. The company constructs and repairs transportation infrastructure, water-treatment facilities, and a wide range of buildings. Tutor Perini has three operating segments: Civil, Building, and Specialty Contractors. A majority of its revenue is generated from the Civil segment, which specializes in public works construction and the replacement and reconstruction of infrastructure. Its civil contracting services include construction and rehabilitation of highways, bridges, tunnels, mass-transit systems, military and other government facilities, and water management and wastewater treatment facilities. Geographically, it derives key revenue from the United States.

Share on Social Networks: